Four 2025 trials spanning novel antibiotic dosing, rapid diagnostics, immunomodulator comparison in COVID-19, and corticosteroids in severe CAP, summarized in full CCR 11-part format.
Verdict | Trial | Journal | Takeaway |
🟡 | JAMA | Dalbavancin missed superiority but performed comparably for S. aureus bacteremia. | |
⚪ | Intensive Care Med | mPCR+PCT missed antibiotic-free-days endpoint but cut cumulative duration. | |
🟢 | Thorax | Tocilizumab and sarilumab improved organ-support-free days; anakinra did not. | |
🔴 | Intensive Care Med | Hydrocortisone showed numerically higher mortality, stopped for futility. |